The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Bayesian randomized phase II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + idarubicin (SGI5 + Ida), 5 days + cladribine (SGI5 + Clad), in untreated patients ≥ 70 years with acute myeloid leukemia (AML).
 
Kiran Naqvi
No Relationships to Disclose
 
Graciela M. Nogueras-Gonzalez
No Relationships to Disclose
 
Cora M. Cheung
No Relationships to Disclose
 
Naveen Pemmaraju
No Relationships to Disclose
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Maro Ohanian
No Relationships to Disclose
 
Nitin Jain
No Relationships to Disclose
 
Koichi Takahashi
No Relationships to Disclose
 
Yesid Alvarado
No Relationships to Disclose
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Xuelin Huang
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)